Baxter International Inc.
BAXHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeBaxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The $13.08B market capitalization puts BAX squarely in large-cap range for its industry. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.
Market Cap
$13.08B
Beta
0.65
P/E (TTM)
—
P/E (Fwd)
12.40
EPS (TTM)
$-1.88
EPS (Fwd)
$2.04
ROE
-14.4%
ROA
2.9%
Cash
$2.15B
Total Debt
$9.67B
Free CF
$1.00B
52W Change
9.2%
Annual Financials
Cash vs Debt
Where BAX stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, BAX finished 20.26% above its 150-day moving average ($21.42) and 22.32% above its 200-day moving average ($21.06). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BAX overbought or oversold?
At the October 16, 2026 close, BAX's RSI(14) was 76.4, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Baxter International Inc. carries $9.67B in total debt against $2.15B in cash reserves — debt is roughly 4.5x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $1.00B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -14.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.9% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $10.06B to $11.24B.
The relatively low beta of 0.65 suggests BAX is a less volatile holding compared to the broader index. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BAX.